However, the stability of the linker must be carefully balanced: a too-weak linker may cause premature drug release, while an overly strong linker may hinder drug delivery. various clinical settings. This review provides a comprehensive overview of pre-clinical and clinical data supporting Belantamab mafodotin as a future therapeutic option for Continue Reading